Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?

Key Takeaways KYMR stock soared 70.7% in 3 months, outperforming its industry and the broader market. A new $750M collaboration with GILD on CDK2 degraders has fueled investor enthusiasm. Despite a Sanofi setback, KYMR earned a $20M milestone and eyes key pipeline advances in 2025-2026.Shares of Kymera (KYMR) have surged 70.7% in the past three months compared with the industry’s gain of 9.7%. The stock has also outperformed the sector and the S&P 500 index during this timeframe.This clinical-stage biotec ...